格拉斯哥评分对肝细胞肝癌患者的预后影响的荟萃分析  

Glasgow prognostic score is a prognostic factor for patients with hepatocellular carcinoma: a systematic review and meta-analysis

作　　者：李慕行[1] 毕新宇[1] 李智宇[1] 黄振[1] 韩玥[2] 周健国[1] 赵建军[1] 张业繁[1] 赵宏[1] 蔡建强[1] 

机构地区：[1]中国医学科学院肿瘤医院腹部外科,北京100021 [2]中国医学科学院肿瘤医院介入治疗科,北京100021

出　　处：《肝癌电子杂志》2015年第3期31-36,共6页Electronic Journal of Liver Tumor

摘　　要：目的系统评价格拉斯哥预后评分(Glasgow Prognostic Score,GPS)对肝细胞肝癌患者预后的影响。方法检索Pub Med(Medline),Embase,Cochrane Library,Web of Science,万方数据和中国知网中的相关文献(自建库至2015年9月),针对GPS与肝细胞肝癌患者预后的关系进行荟萃分析。结果经过严格筛选,共纳入10篇相关文献。荟萃分析提示高GPS评分的肝细胞肝癌患者的总生存期较低GPS评分者总生存期短(HR:2.156,95%CI:1.696~2.740,P<0.001)。高GPS评分的肝细胞肝癌患者大多Child–Pugh分级较高[odds ratio(OR)=25.979,95%CI:6.159~109.573,P<0.001]。本荟萃分析发表偏倚显著。结论 GPS可能是肝细胞肝癌患者的预后指标,其预后价值也需更多严格设计的临床研究加以巩固证实。Objective We performed the meta-analysis to evaluate the prognostic value of GPS in HCC patients. Methods Pub Med(Medline), Embase, Cochrane Library, Web of Science, Chinainfo and Chinese National Knowledge Infrastructure were searched. Studies analyzing the predictive value of GPS in patients' survival outcome were screened and identified. Pooled analysis of the hazard ratio(HR) or odds ratio(OR) with 95% confidence interval(CI) was conducted. Results A total of 10 studies met the inclusion criteria and were taken into the meta-analysis. Patients with elevated GPS had inferior overall survival(OS) than that of patients with decreased GPS(HR = 2.156, 95%CI: 1.696-2.740, P < 0.001). A tendency towards shorter progression-free survival(PFS) in patients with elevated GPS was observed(HR = 1.755, 95%CI: 0.943-3.265, P = 0.076). And patients with elevated GPS tended to be at advanced Child-Pugh class(odds ratio(OR) = 25.979, 95%CI: 6.159-109.573, P < 0.001). Conclusions GPS is a potential prognostic factor in patients with HCC.

关 键 词：格拉斯哥预后评分 肝细胞肝癌 预后 荟萃分析 

分 类 号：R735.7[医药卫生—肿瘤]